Drug Profile
PNQ 201
Alternative Names: Ado A-2B antagonist; PNQ-201Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in India (PO)
- 16 Jun 2020 PNQ 201 is still in preclinical development for Colorectal cancer in India
- 16 Jun 2020 PNQ 201 is available for licensing as of 16 Jun 2020. https://impetisbiosciences.com/